Bristol Myers Squibb shares moved lower after a report said the drugmaker has been in talks about a potential merger with AstraZeneca. Based on the two companies' market values, the combination would be worth about $400 billion, making it one of the largest pharmaceutical deals ever discussed.
The market response suggested investors were not convinced the idea would create value. The available report indicates Wall Street has become increasingly skeptical about the logic of pairing Bristol Myers Squibb with AstraZeneca, even with the scale such a transaction would bring.
As of Friday's close, AstraZeneca carried a market capitalization of about $264 billion, while Bristol Myers Squibb was valued at roughly $133 billion. Those figures help explain why the possible tie-up has drawn attention across the healthcare and mergers-and-acquisitions space.
For now, the focus remains on whether talks lead anywhere and how investors judge the strategic fit. With a deal of this size, scrutiny would likely center on valuation, execution risk, and whether the combined company could justify the complexity of such a massive pharmaceutical merger.
